Rxo annual return on equity
2021
2022
2023
2024
2025
Rxo Return on Equity (ROE) Growth & History (RXO)
Rxo's return on equity was −6.34% for fiscal 2025.
View full Rxo company overviewRxo annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −6.34% | +19.95 pp |
| 2024 | 2024-12-31 | −26.29% | −26.97 pp |
| 2023 | 2023-12-31 | 0.68% | −10.43 pp |
| 2022 | 2022-12-31 | 11.10% | −2.93 pp |
| 2021 | 2021-12-31 | 14.03% | — |
Rxo quarterly return on equity
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −0.60% | −0.03 pp |
| Q1 2026 | 2026-03-31 | −2.36% | −0.42 pp |
| Q4 2025 | 2025-12-31 | −2.95% | −1.42 pp |
| Q3 2025 | 2025-09-30 | −0.88% | +20.90 pp |
| Q2 2025 | 2025-06-30 | −0.57% | +0.64 pp |
| Q1 2025 | 2025-03-31 | −1.94% | +0.61 pp |
| Q4 2024 | 2024-12-31 | −1.53% | −1.87 pp |
| Q3 2024 | 2024-09-30 | −21.78% | −21.61 pp |
| Q2 2024 | 2024-06-30 | −1.21% | −1.72 pp |
| Q1 2024 | 2024-03-31 | −2.55% | −2.55 pp |
| Q4 2023 | 2023-12-31 | 0.34% | +0.80 pp |
| Q3 2023 | 2023-09-30 | −0.17% | −1.34 pp |
| Q2 2023 | 2023-06-30 | 0.51% | — |
| Q1 2023 | 2023-03-31 | 0.00% | — |
| Q4 2022 | 2022-12-31 | −0.46% | — |
| Q3 2022 | 2022-09-30 | 1.17% | — |
Rxo return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Rxo's return on equity decreased from 14.03% to −6.34%, a change of −20.37 percentage points. The latest reported quarter, Q2 2026, shows −0.60%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rxo source filings ↗